Exelixis stock
EXELNASDAQExelixis, Inc., HealthcareISIN US30161Q1040
90Score 90 out of 100, Strong
Price and trend
87 / 100
Price history
+64% in one yearThe chart shows daily closes over 20 years, adjusted for stock splits and without dividends. Click into the chart to set a price alert at that price.
Above the 200-day line: the price is 36% above it.
Since November 2025 the 50-day line has been above the 200-day line; the trend has turned up.
Normal: the price is neither overheated nor sold off (RSI 65).
The price is 2.8% below its 52-week high. Largest decline in 20 years: 90% (February 2011 to December 2014).
Chart figures for advanced users
- SMA 50$61.86
- Average price of the last 50 trading days, shows the short-term trend.
- SMA 200$51.97
- Average price of the last 200 trading days, shows the long-term trend.
- RSI (14)65
- Relative strength over the last 14 days on a scale from 0 to 100. Above 70 the price counts as overheated, below 30 as sharply fallen.
- MACDabove the signal line
- Compares a fast and a slow price average. Above its signal line momentum is rising, below it momentum is fading.
- Support$40.74
- The lowest closing price of the last twelve months.
- Resistance$72.75
- The highest closing price of the last twelve months.
Snapshot
Computed from the data by fixed rules, no AI
- Exelixis, Inc. belongs to the Biotechnology industry (United States) and, with a market value of $17.77B, is number 20 of 296 companies in its industry on MEQIRI.
- In fiscal 2025 it reported revenue of $2.32B (up 7% year on year) and earnings of $782.57M (up 50.1%).
- For fiscal 2026, analysts expect on average revenue of $2.56B (up 10.2%) and adjusted earnings per share of $3.71 (up 20.1%).
Show more
- MEQIRI Score 90 out of 100 (Strong): rank 1 of 714 in Healthcare, median 53.
- The P/E is 20.4 (Biotechnology median 21.3, own median of recent years 25).
- Our model puts fair value at $94.45, with the price 25% below it.
In plain words
The numbers on this page in plain words, written by an AI
Strengths
- Earnings per share growingUp 51.6% a year since 2020.Growth 97
- High return on capitalReturn on invested capital 55.8% in fiscal 2025, Biotechnology median −24.3%.Profitability 98
- High marginNet margin 35.5% over the last 12 months, Biotechnology median −93.3%.Profitability 98
Weaknesses
- Margin may fall backOperating margin 37.6%, average of the prior years 12.5%, which ranged from 9.3% to 27.9%. After peaks like this, the margin was more than a quarter lower two years later in 44 of 100 cases, against 24 of 100 for other companies with high margins.
Its standout strengths are profitability and growth.
Daily figure as of 12 Nov 2026
How the score is calculatedScore overview
Fundamentals are strong, with stable profits and strong cash generation.
Score history
The full history of up to 20 years comes with MEQIRI Pro.
See plansCrash risk low
How well MEQIRI warnsOne of the 30% with the lowest crash risk among stocks ranked 101 to 1,000.
From 2016 to 2025, 9 in 100 such stocks fell 30% or more within a year, against a group average of 15 in 100.
What drives the risk
- high growth grade (crashed more often in the backtest)
What lowers it
- solid fundamentals
- price near its 52-week high
- stable momentum
Valuation
Valuation signal
Significantly undervaluedIn our model the price counts as cheap below $72.65 and expensive above $134.92 (uncertainty medium, based on the price swings of the past year).
The two parts of the fair value come to $115.21 (cash-flow model) and $73.68 (industry comparison), and the gap between them shows how uncertain the estimate is. The price is below both.
Calculated with a cost of equity of 9.3%. At 10.3% the fair value would be $85.12, at 8.3% it would be $108.01.
Valuation metrics
Half from the cash-flow model, half from earnings times the industry P/E (21.3).
Calculate with your own assumptionsCompany performance
This shows several years of history with an automatic assessment.
Revenue
In the twelve months to 2 Oct 2026, revenue rose 9.1% on the twelve months before. Revenue has grown strongly since 2006, at around 18% per year.
Margins
- Gross margin
- Operating margin
- Net margin
In fiscal 2025: gross 96%, operating 38%, net 34%.
Debt & balance sheet
latest quarterThe balance sheet is solid, with low debt and comfortable interest coverage.
Earnings
- Next earnings
- 9 Feb 2027in 89 days
- Last reported
- 29 Oct 2026EPS reported $0.94 (expected $0.89)above expectations
Analyst estimates
Analysts have raised their 2027 earnings estimate by 5.0% since 15 Oct 2026.
- Earnings per share
- $3.71+5.0%
- Revenue
- $2.56B+0.2%
- Earnings per share
- $4.19+2.0%
- Revenue
- $2.88B−0.5%
MEQIRI has stored the estimates since 15 Oct 2026. Until 30 days are available, the card shows the change since that day. Mean estimate according to Financial Modeling Prep. No price target and no recommendation.
Company outlook lowered
Share price after the results: −6.8%2026 revenue guidance lowered and narrowed, midpoint down $50 million, due to a slower ramp of the new indication; R&D expense guidance also cut by $50 million.
“We are lowering and narrowing our total revenues and net product revenue guidance, which lowers the midpoint by $50 million when compared to our previous guidance. This updated financial guidance reflects modestly slower growth in 2026 due to a more gradual ramp for the NET indication than the original projection.”The outlook is not part of the score and not a recommendation to buy or sell.
From the earnings call on 5 Aug 2026 (fiscal Q2 2026), read by AI.
Insiders
Open-market purchases and sales by executives, board members and major holders
No open-market purchases in the last 6 months. 7 insiders sold, $7.08M in total.
Sales say less than purchases: many insiders sell on a fixed plan, for taxes or to diversify.
- Beckerle Mary CSale
10 Aug 2026, Board
- Shares
- 9,812
- Price
- $53.66
- Value
- $526,512
- Wyszomierski Jack LSale
1 Jun 2026, Board
- Shares
- 3,925
- Price
- $50.55
- Value
- $198,409
- Eckhardt Sue GailSale
1 Jun 2026, Board
- Shares
- 9,812
- Price
- $50.14
- Value
- $491,974
Show 4 more
- Aftab DanaSale
26 May 2026, EVP, Research and Development
- Shares
- 43,451
- Price
- $50.35
- Value
- $2.19M
- Haley Patrick J.Sale
20 May 2026, EVP, Commercial
- Shares
- 32,110
- Price
- $49.81
- Value
- $1.6M
- Senner Christopher J.Sale
18 May 2026, EVP and CFO
- Shares
- 34,901
- Price
- $50.00
- Value
- $1.75M
- Hefti BrendaSale
18 May 2026, SVP and General Counsel
- Shares
- 6,625
- Price
- $50.21
- Value
- $332,641
Source: Form 4 filings with the US Securities and Exchange Commission. Grants, option exercises, gifts and tax withholdings are hidden. Not a recommendation to buy.
What happened at Exelixis
The key events of the last six months from our own data. A click takes you to the matching card.
Sector comparison
714 rated companies in Healthcare
- This company
- 90
- Sector median
- 53
Categories against the sector median
The median is the middle value: half of the companies in the sector lie above it, half below. Categories with too few comparable companies are left out.
Competitors in Biotechnology
The next larger and next smaller companies by market value
- IncyteINCY $24.92B70
- BioNTechBNTX $21.73B37
- Alnylam PharmaceuticalsALNY $21.41B57
- Innovent Biologics1801.HK $19.29B61
- Neurocrine BiosciencesNBIX $17.65B77
- Ascendis PharmaASND $17.06B69
- Jazz PharmaceuticalsJAZZ $15.93B66
- BridgeBio PharmaBBIO $15.49B50
ETFs that hold Exelixis
Held by 16 ETFs on Xetra. Shown per index: the ETF with the largest weight.
| ETF | Weight | Cost | Fund size |
|---|---|---|---|
| iShares Healthcare Innovation UCITS ETF2B78 | 1.52% | 0.40% | €1.49B |
| iShares Nasdaq US Biotechnology UCITS ETF2B70 | 1.12% | 0.35% | €1.21B |
| iShares Ageing Population UCITS ETF2B77 | 0.64% | 0.40% | €807M |
Show 5 more
| State Street SPDR S&P 400 U.S. Mid Cap UCITS ETF (Acc)SPY4 | 0.51% | 0.30% | €5.27B |
| Invesco Global Buyback Achievers UCITS ETFBBCK | 0.31% | 0.39% | €188.08M |
| iShares MSCI USA Small Cap CTB Enhanced ESG UCITS ETFSXRG | 0.24% | 0.43% | €2.48B |
| iShares MSCI World Small Cap CTB Enhanced ESG UCITS ETFCBUG | 0.17% | 0.35% | €434.1M |
| State Street SPDR MSCI World Small Cap UCITS ETF (Acc)ZPRS | 0.16% | 0.45% | €1.53B |
Holdings as reported by the funds via FMP, excluding swap ETFs (their holdings are only collateral).
Data status and sources
- Score
- Daily value of 12 Nov 2026, recalculated nightly
- Price
- Closing price of 11 Nov 2026
- Latest annual report
- Fiscal year 2025, period end 2 Jan 2026
- Source
- Financial statements, ratios and prices from Financial Modeling Prep (FMP), based on the company's reports. MEQIRI calculates the score and fair value from them.
Mandatory disclosures for this rating
- ; time horizon around 12 months
- Rated Strong, published since 7 Nov 2026 (in the score history since 31 Oct 2024)
- Valuation signal Undervalued since 7 Nov 2026
- End-of-day prices, metrics cached for up to 24 hours
- Score and fair value are estimates from a disclosed model. They are not facts and not a price target.
- Produced by SSM Ventures UG (haftungsbeschränkt), responsible person Sven Brostmeyer, Managing Director, automatically according to the disclosed model.
- Not investment advice. Losses up to and including a total loss are possible. Personal circumstances are not considered.